Abstract: This disclosure relates to compositions, devices and methods of detecting the presence of molecules and optionally quantifying forces associated with molecular interactions on the surface of cells and other lipids. In certain embodiments, devices disclosed herein can be used to detect forces through cell surface receptors. In other embodiments, the devices can be used to detect the presence or absence of molecules on cells or other particles or detect the changes in cell morphology after ligand receptor binding.

Abstract: The present invention relates to a method for expressing a target protein on the surface of a microorganism using Bacillus anthracis exosporium protein. More particularly, to an expression vector constructed such that it comprises bclA gene encoding Bacillus anthracis exosporium protein BclA or fragments thereof as a cell surface anchoring motif and the target protein can be expressed on the surface of a cell in a form fused with BclA or a fragment thereof when the gene encoding the target protein is expressed in a host cell, as well as, a method for expressing a target protein on the surface of a microorganism using the vector.

Abstract: Described herein are kits and components thereof used for a multiplexed analysis of a set of cytokines.

Abstract: Affinity tags and ligands comprising a PDZ domain peptide and a PDZ binding carboxy terminal peptide and related engineered protein, engineered labels, compositions, methods and systems.

Abstract: Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least 5 genes in a sample from the subject, e.g., a blood sample, is assayed to obtain a gene expression result for the at least 5 genes. The obtained gene expression result for the at least 5 genes is then employed to determine whether the subject has a graft tolerant phenotype. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.

Abstract: A lateral test flow arrangement for a test molecule is disclosed, comprising: a test strip for transporting an analyte away from a sampling region and towards an absorbing region, the test strip having therein and remote from the sampling region, a test region for functionalization with a molecule which binds to the test molecule or to a conjugate of the test molecule; a sensing test capacitor having electrodes extending across the test strip at least partially aligned with the test region and being physically isolated therefrom; a reference test capacitor having electrodes extending across the test strip and being physically isolated therefrom; and an electronic circuit configured to measure a time-dependant capacitance difference between the sensing test capacitor and the reference test capacitor.

Abstract: Provided herein are multiplex assays for determining whether an individual is or has been infected with Hepatitis B virus, and the stage of infection or resolution. In addition, the multiplex system can discriminate between vaccinated subjects and subjects susceptible to Hepatitis B infection.

Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.

Abstract: This document provides methods and materials involved in performing flow cytometry assay methods. For example, flow cytometry assay methods and kits are provided.

Abstract: A method for the risk detection, early diagnosis, prognosis, and monitoring of Alzheimer's disease in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with Alzheimer's disease, or an earlier sample from the individual of interest.

Abstract: The present invention relates, inter alia, to polyspecificity reagents, methods of making the same, and methods of using the same in, inter alia, the selection, screening, enrichment, and identification of non-polyspecific, and thus developable, polypeptides.

Abstract: The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (BC) and prostate cancer (CaP). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers.

Abstract: A method of determining biosimilarity of a sample composition to a reference composition, including: exposing a test cell system to a sample composition so that the test cell system responds to the sample composition by change in transcription factor activity in the test cell system; generating from the test cell system response an output correlative to the change of transcription factor activity in the test cell system; and determining from comparison of said output with a transcription factor activity reference standard for the reference composition, the biosimilarity of the sample composition to the reference composition. Computer systems and kits for carrying out the determination of biosimilarity of compositions are also described, in which biosimilarity of compositions ranging from simple molecules to complex mixtures can be readily and accurately determined by transcription factor activity analysis.

Abstract: A thermostable glycosidase enzymes derived from various Thermococcus, Staphylothermus and Pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.

Abstract: The invention provides methods, compositions and kits for the detection and treatment of bladder cancer.

Abstract: Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS.

Abstract: A point of care immunization system based upon microfluidics and micro-titration technologies to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of uniquely shaped and color distinguishing sample and test cartridges, with said test cartridges configured to meet healthcare requirements of national governing bodies. A point of care system including an easy access vaccine storage device with indicators to provide data on viability of stored vaccines.

Abstract: A chemical sensor comprising: a hydrogel layer, comprising one or more molecular recognition agents and a 2DPC self-assembling array; and a mirror layer. A method for analyzing a sample or bodily fluid, comprising: obtaining a sample or bodily fluid; placing an amount of the sample or bodily fluid onto a chemical sensor, comprising: a hydrogel layer, comprising a molecular recognition agent and a 2DPC self-assembling array; a tethering hydrogel layer; a mirror layer; and a membrane filter layer, allowing the bodily fluid to interact with the hydrogel layer; and allowing ambient or artificial light to pass through the hydrogel layer onto the mirror layer and observing a change in diffraction versus a control.

Abstract: Microarray compositions suitable for analysis by one or several spectrographic methods are disclosed. In an embodiment, a microarray composition includes a three-dimensional solid support and a plurality of reactive microbeads positioned on the solid support in spatially distinct and addressable locations.

Abstract: The present invention relates to a method for absolute quantification of polypeptides.

Abstract: The present invention provides methods, compositions and kits for the detection of Alzheimer's disease (AD) diagnostic biomarkers, for the diagnosis of AD, for the identification of a subject at risk for developing AD, and for the generation of patient-specific AD diagnostic biomarker profiles.

Abstract: A diagnostic assay for cancer such as lung cancer is disclosed. The assay can also be used to follow patients during treatment and for assessment of disease relapse after treatment. The assay utilizes biomarkers for tumor formation identified in a transgenic mouse model. The assay is used to identify a therapeutic indication for a patient based on the patient's biomarker expression. The biomarker and fragments thereof are also useful for treating cancer, for example lung or colon cancer.

Abstract: Methods are provided for evaluating an oocyte for fertilization and implantation comprising analysis of gene expression in cumulus cells wherein the detected genes or polypeptides include at least SPSB2 and TP53I3. For example, methods are provided for determining whether a cumulus cell expresses, or does not express, one or more of a group of markers identified as differently expressed between cumulus cells associated with chromosomally normal oocytes and cumulus cells associated with chromosomally abnormal oocytes. Methods are provided for the detection of marker expression of differentially expressed genes at the RNA level, as well as at the protein level.

Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.

Abstract: Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication.

Abstract: The present invention provides a kit for determining male fertility including a container system containing a plurality of enzyme-linked antibodies one of each capable of binding to analytes Atp6v0a2, G-CSF, MIP 1?, and MCP-1. The kit further includes suitable packaging and a set of instructions for using the enzyme-linked antibodies with a seminal sample to determine the fertility of the sample.

Abstract: A method of diagnosing an immune disease, or a predisposition thereto, in a subject is disclosed.

Abstract: The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others.

Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

Abstract: The invention relates to the field of medical diagnostics. In particular, it relates method and kits for identification and classification of IgE-related diseases, e.g. Type I hypersensitivity, as well as for monitoring of treatment efficacy, for instance anti-IgE therapy.

Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterisation and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.

Abstract: The present invention provides methods to analyze oxidized phospholipids (OxPL) on apolipoprotein B-100 in patients at high risk or with documented coronary artery disease (CAD) or acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction or suspected of being at risk for ACS. Such methods are useful for diagnostic purposes and for monitoring the effects of dietary interventions or with drugs such as statins. More particularly, the disclosure provides methods for determining OxPL/apoB ratios as indices of atherosclerosis regression and plaque stability.

Abstract: A protein chip including at least a substrate having a plurality of steps which are regularly arranged on one surface thereof; a plurality of metallic microstructures arranged in the steps; and a lipid vesicle in which an outer surface thereof is modified by a functional group and a protein is present in a lipid bilayer thereof. The metallic microstructures and the lipid vesicle are bound via the functional group to provide the protein on the substrate.

Abstract: The disclosure relates to the extraction and detection of pathogens using carbohydrate-functionalized biosensors. Immobilized carbohydrate moieties on the biosensor provide a means for non-specific binding of a plurality of target analytes. When a sample containing the target analyte is applied or otherwise transported to the biosensor detection surface, non-specific binding interactions between the carbohydrate moiety and the analyte immobilize/retain the analyte at the detection surface. The carbohydrate moiety is a stable binding pair member that allows on-sensor rinsing of a sample to enhance detection of an analyte in the sample. Specific analyte identification can be achieved with an analyte probe having a detection moiety and a binding pair member specific to the target analyte of interest.

Abstract: The present invention provides methods and devices for detecting the presence of biomolecules in a biological sample, such as PVL, PBP2a and SPA.

Abstract: The present invention relates to an exemplary in vitro diagnostic (IVD) device used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, cerebrospinal fluid (CSF). The inventive IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format wither to a display device or to a storage device internal or external to the IVD.

Abstract: Some aspects of this invention provide reagents and methods for the sensitive, quantitative and simultaneous detection of target analytes in complex biological samples by liquid chromatography tandem mass spectrometry (LC MS/MS). Some aspects of this invention provide affinity reagents encoded with mass reporters for the sensitive and quantitative translation of an analyte of interest into a mass tag. The reagents and methods provided herein have general utility in analyte detection and encoding, for example, in biomolecular profiling, molecular diagnostics, and biochemical encoding.

Abstract: A set of biomarkers (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use are disclosed.

Abstract: The invention provides for a method for distinguishing spore preparation procedures using spore molecular signatures, the method comprising harvesting spores from a sample; extracting molecules from the spores, fractionating the extracted molecules for analysis; generating molecular signatures from the fractionated molecules, and comparing the molecular signatures to a library of molecular signatures.

Abstract: The present disclosure provides methods for detecting the presence of a cancer stem cell and their use in cancer prognosis, evaluating risk of cancer metastasis, identifying or validating drug candidates, and determining treatment efficacy. It also provides kits useful for detecting the presence of cancer stem cells as well as methods of treating cancer using CAIX inhibitors.

Abstract: Multiplexed microarrays, multiplexed microarray cassettes, and methods for fabricating multiplexed microarrays are disclosed. In some embodiments, the multiplexed microarrays include a substrate, a chamber layer, and at least one channel layer. The topmost channel layer forms a port layer and may be compressible. The multiplexed microarrays may also include a compressible or non-compressible cover or sealing film. The multiplexed microarray cassette includes a base and may also include a cover. The base of the multiplexed microarray cassette includes a plurality of tracks to receive corresponding multiplexed microarrays.

Abstract: A method of patterning a surface of a substrate comprising: (a) applying a coating to the surface to form a coated surface, and (b) treating the coated surface with a patterned microplasma comprising a plurality of localised microplasma discharges such that localised regions of the coated surface are selectively exposed to the localised microplasma discharges to form exposed localised regions and unexposed regions that have not been substantially exposed to a microplasma discharge; wherein the coating at the exposed localised regions is modified by the patterned microplasma and the coating at the unexposed regions is substantially unmodified to form a patterned surface on the substrate.

Abstract: Provided is a multi-reaction biosensor capable of generating various kinds of reaction signals through introduction of a sample at a time. The multi-reaction biosensor having a capillary flow path through which a sample is introduced, comprises a reaction substrate configured to form at least two wall surfaces of a plurality of wall surfaces that form the capillary flow path, and configured to generate and transmit a reaction signal according to a reaction with the introduced sample; and a base substrate coupled to the reaction substrate such that the capillary flow path has a polygonal cross-sectional shape, and configured to form a wall surface other than the wall surfaces formed by the reaction substrate. Accordingly, various kinds of reaction signal can be generated through introduction of a sample at a time.

Abstract: A method of preparing a species-specific phosphorylation site peptide array for a target organism comprising: a) selecting a plurality of known non-target organism (NTO) phosphorylation site sequences and cognate known NTO phosphorylation polypeptide sequences from one or more NTO, each of the known NTO phosphorylation site sequences comprising at least 5 residues and less than 30 residues; b) identifying a matching target organism (TO) phosphorylation site sequence and cognate TO phosphorylation polypeptide sequence for one or more of the known NTO phosphorylation site sequences; c) determining the matching TO phosphorylation site sequences that correspond to orthologue polypeptides of the cognate known NTO phosphorylation polypeptide sequences; d) selecting the matching TO phosphorylation site sequences determined to correspond to orthologue polypeptides for inclusion on the array; wherein the matching TO phosphorylation site sequences that correspond to orthologue polypeptides are determined by calculating

Abstract: The present invention is directed to a method for obtaining an in vitro pharmacological model of a recombinant protein drug in a given host. A plurality of biomolecules are selected which are known or suspected to influence pharmacology of the recombinant protein in the host via a binding interaction with the recombinant protein. The recombinant protein is contacted with each selected biomolecule and the binding kinetics parameters for each interaction are determined using a binding assay. These steps are then repeated with all selected biomolecules to produce a plurality of binding kinetics parameters for the selected biomolecules. The combined results provide an in vitro pharmacological model of the recombinant protein in the host. The in vitro pharmacological model may then be used in several applications, such as optimizing new batches of recombinant protein drugs, developing biosimilar or bio-better drug candidates.

Abstract: The invention relates to methods and kits for characterizing and diagnosing autism spectrum disorder in an individual based on gene expression levels.

Abstract: The disclosure provides biomarker panels, methods and kits for determining the probability for preeclampsia in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preeclampsia relative to matched controls. The present disclosure is further based, in part, on the unexepected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preeclampsia in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preeclampsia, monitoring of progress of preeclampsia in a pregnant female, either individually or in a panel of biomarkers.

Abstract: Disclosed herein are methods, systems, mediums, and kits for use in phenotyping antibody responses via devices such as surface plasmon resonance devices. Such phentypes can include total target-specific antibody titers, quantitative isotype distribution of the target-specific antibodies, and/or epitope specificity of the target-specific antibodies. Other methods, systems, mediums, and kits are also disclosed.

Abstract: Compositions and methods useful for diagnosis and prognosis of cancer are provided.

Abstract: A genetic means of identifying “pregnancy competent” oocytes is provided. The means comprises detecting the level of expression of one or more genes that are expressed at characteristic levels (upregulated or downregulated) in cumulus cells derived from pregnancy competent oocytes. This characteristic gene expression level, or pattern referred to herein as the “pregnancy signature”, also can be used to identify subjects with underlying conditions that impair or prevent the development of a viable pregnancy, e.g., pre-menopausal condition, other hormonal dysfunction, ovarian dysfunction, ovarian cyst, cancer or other cell proliferation disorder, autoimmune disease and the like.